Cellectis (CLLS) Net Income towards Common Stockholders (QoQ) (2015 - 2026)
Powered by 
Analysis
Cellectis (CLLS) Net Income towards Common Stockholders (QoQ) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.52% |
| Mar 31, 2026 | -6,922,976.92% |
| Dec 31, 2025 | -100.04% |
| Sep 30, 2025 | 102.48% |
| Jun 30, 2025 | -31.87% |
| Mar 31, 2025 | -403.95% |
| Dec 31, 2024 | 125.69% |
| Sep 30, 2024 | 8.76% |
| Jun 30, 2024 | -547.81% |
| Mar 31, 2024 | 113.50% |
| Dec 31, 2023 | -139.07% |
| Sep 30, 2023 | -49.33% |
| Jun 30, 2023 | 61.07% |
| Mar 31, 2023 | -12.15% |
| Dec 31, 2022 | 5.80% |
| Sep 30, 2022 | -50.25% |
| Jun 30, 2022 | 40.63% |
| Mar 31, 2022 | -27.66% |
| Dec 31, 2021 | 33.19% |
| Sep 30, 2021 | 6.28% |